Hebo Pharmaceutical Bartolizumab completes the first patient's administration for the Phase III trial of systemic myasthenia gravis

Suzhou, China, Cambridge, Massachusetts, and Rotterdam, the Netherlands, September 27, 2021 /PRNewswire/ - Hebo Pharmaceutical (stock code: 02142.

Hebo Medicine is committed to building bartolizumab (HBM9161) into a series of product pipelines to treat various autoimmune diseases mediated by pathogenic IgG to meet the current huge medical needs.

Professor Zhao Zhongbo, the chief investigator of the bartolizumab clinical trial and the chief physician of the Department of Neurology, Huashan Hospital Affiliated to Fudan University, said: "Earlier, the phase II clinical study of bartolizumab (HBM9161) for the treatment of systemic myasthenia gravis has been successfully completed.

Dr.

About Bartolizumab (HBM9161)

Bartolizumab (HBM9161) is a fully human monoclonal antibody (mAb) that can block the binding of FcRn-IgG to each other, accelerate the elimination of IgG in the body, and achieve effective treatment of pathogenic IgG-mediated autoimmunity The effect of the disease

About generalized myasthenia gravis (gMG)

Myasthenia gravis (MG) is an acquired autoimmunity mediated by antibodies such as anti-acetylcholine receptor (AChR) immunoglobulin G (IgG) and anti-muscle-specific tyrosine kinase (Anti-MuSK) IgG Disease, which leads to impaired transmission of neuromuscular junctions, manifested by weakness in skeletal muscle contraction

At present, the main treatment methods for MG include cholinesterase inhibitors, glucocorticoids and immunosuppressants, but their efficacy and safety cannot meet the clinical needs of various patients

About Hebo Pharmaceutical

Hebo Pharmaceutical (stock code: 02142.

Harbour Mice®, Hebo's own antibody technology platform, can generate fully human monoclonal antibodies in dual, dual light chain (H2L2) and heavy chain only (HCAb) forms